← Back to Screener
Kazia Therapeutics Limited American Depositary Shares (KZIA)
Price$10.92
Favorite Metrics
Price vs S&P 500 (26W)35.68%
Price vs S&P 500 (4W)27.33%
Market Capitalization$81.20M
All Metrics
Book Value / Share (Quarterly)$0.01
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)279.24%
Cash Flow / Share (Quarterly)$-0.00
Price vs S&P 500 (YTD)42.50%
Gross Margin (TTM)77.70%
Net Profit Margin (TTM)-9259.16%
EPS (TTM)$-0.01
10-Day Avg Trading Volume0.23M
EPS Excl Extra (TTM)$-0.01
Revenue Growth (5Y)11.58%
EPS (Annual)$-0.03
ROI (Annual)-147.79%
Gross Margin (Annual)77.60%
Net Profit Margin (5Y Avg)-261385.72%
Cash / Share (Quarterly)$0.01
Revenue Growth QoQ (YoY)461.28%
ROA (Last FY)-341.56%
Revenue Growth TTM (YoY)-89.49%
EBITD / Share (TTM)$-0.01
ROE (5Y Avg)-97.91%
Operating Margin (TTM)-10667.11%
Cash Flow / Share (Annual)$-0.01
P/B Ratio3.40x
P/B Ratio (Quarterly)0.32x
EV / Revenue (TTM)418.37x
Net Interest Coverage (TTM)-77.23x
ROA (TTM)-59.09%
EPS Incl Extra (Annual)$-0.03
Current Ratio (Annual)0.35x
Quick Ratio (Quarterly)2.86x
3-Month Avg Trading Volume0.21M
52-Week Price Return153.16%
Tangible BV / Share (Quarterly)$0.01
P/S Ratio (Annual)1387.76x
Asset Turnover (Annual)0.02x
52-Week High$17.40
Operating Margin (5Y Avg)-265734.98%
EPS Excl Extra (Annual)$-0.03
26-Week Price Return39.66%
Quick Ratio (Annual)0.32x
13-Week Price Return55.28%
Total Debt / Equity (Annual)0.15x
Current Ratio (Quarterly)2.87x
Enterprise Value$73.799
Revenue / Share Growth (5Y)-25.98%
Asset Turnover (TTM)0.01x
Inventory Turnover (Annual)1.54x
Pretax Margin (Annual)-19691.23%
Cash / Share (Annual)$0.00
3-Month Return Std Dev111.43%
Gross Margin (5Y Avg)70.65%
ROE (Last FY)-169.83%
Net Interest Coverage (Annual)-7.40x
EPS Basic Excl Extra (Annual)$-0.03
Receivables Turnover (TTM)34.73x
Total Debt / Equity (Quarterly)0.31x
EPS Incl Extra (TTM)$-0.01
Receivables Turnover (Annual)7606.56x
ROI (TTM)-20.66%
P/S Ratio (TTM)642.46x
Pretax Margin (5Y Avg)-265457.64%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)123.33%
Year-to-Date Return45.14%
5-Day Price Return9.89%
EPS Normalized (Annual)$-0.03
ROA (5Y Avg)-124.54%
Net Profit Margin (Annual)-18159.65%
Month-to-Date Return34.41%
EBITD / Share (Annual)$-0.03
Operating Margin (Annual)-21075.44%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-91.00%
LT Debt / Equity (Quarterly)0.32x
EPS Basic Excl Extra (TTM)$-0.01
P/TBV (Quarterly)0.33x
Inventory Turnover (TTM)1.54x
Pretax Margin (TTM)-9913.15%
Price vs S&P 500 (13W)54.59%
Beta1.85x
P/FCF (Annual)247.20x
Revenue / Share (TTM)$0.00
ROE (TTM)-27.01%
52-Week Low$2.86
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KZIAKazia Therapeutics Limited American Depositary Shares | 642.46x | -89.49% | 77.70% | — | $10.92 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Kazia Therapeutics is an oncology-focused biotechnology company developing targeted cancer therapies. Its lead program, Paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway designed to treat brain cancers. The company maintains operations in Australia and the United States and has a portfolio of additional development candidates across various cancer indications.